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Quantitative TaqMan® real-time PCR assays for gene
expression normalisation in feline tissues
Abstract
Gene expression analysis is an important tool in contemporary research, with real-time PCR as the
method of choice for accurate and fast quantification of mRNA transcription levels. Co-analysis of
reference genes is crucial for expression normalization. Since, reference gene expression may vary, e.g.,
among different species and tissues, their applicability must be tested prior to use in expression studies.
The domestic cat is an important study subject in medical research (e.g. animal model for infectious
diseases or endocrine disorders) and in veterinary medicine. Little is known about feline reference genes
and their application in TaqMan® real-time PCR assays. The aim of the present study was to develop
TaqMan® assays for eight potential feline reference genes and to test their applicability for feline
samples, including blood, lymphoid, endocrine, and gastrointestinal tissues from clinically healthy cats,
and neoplastic tissues. RNA extraction from tissues was optimized for minimal gDNA contamination
without use of a DNase treatment. Candidate reference genes included: ABL (v-abl Abelson murine
leukemia viral oncogene homolog), ACTB (ß-actin), B2M (ß-2-microglobulin), GUSB
(ß-glucuronidase), HMBS (hydroxymethyl-bilane synthase), HPRT (hypoxanthine
phosphoribosyltransferase), RPS7 (ribosomal protein S7), YWHAZ (tryptophan 5-monooxygenase
activation protein, zeta polypeptide). The assays were tested together with previously developed
TaqMan® assays for feline GAPDH (glyceraldehyde-3-phosphate dehydrogenase) and the universal
18S rRNA gene. The suitability of the candidate genes was assessed using the geNorm and NormFinder
programs. A significant difference was found among the expression levels of the ten candidate reference
genes (pKW < 0.001): the expression levels for the 18S rRNA gene were > 106-times higher than those
of ABL and HMBS. This will allow matching the expression level of the reference genes with that of
the target genes. The presence of pseudogenes was confirmed for four of the eight tested genes. The
study confirmed that reference gene expression stability varies considerably among the tested feline
tissues. No reference gene was suitable for optimal gene expression normalization in all tissues. For the
majority of the tissues, two to four reference genes were found to be a recommendable number of genes
for accurate normalization. ACTB, RPS7, and ABL were among the most stable reference genes in the
studied tissues, while HPRT, 18S rRNA gene and GAPDH were among the least stable ones. The
present study yields essential information on the correct choice of feline reference genes depending on
the tissues analyzed.
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1 Summary 
Gene expression analysis is an important tool in contemporary research, with 
real-time PCR as the method of choice for accurate and fast quantification of 
mRNA transcription levels. Co-analysis of reference genes is crucial for 
expression normalization. Since, reference gene expression may vary, e.g., 
among different species and tissues, their applicability must be tested prior to 
use in expression studies. The domestic cat is an important study subject in 
medical research (e.g. animal model for infectious diseases or endocrine 
disorders) and in veterinary medicine. Little is known about feline reference 
genes and their application in TaqMan® real-time PCR assays. The aim of the 
present study was to develop TaqMan® assays for eight potential feline 
reference genes and to test their applicability for feline samples, including 
blood, lymphoid, endocrine, and gastrointestinal tissues from clinically healthy 
cats, and neoplastic tissues. RNA extraction from tissues was optimized for 
minimal gDNA contamination without use of a DNase treatment. Candidate 
reference genes included: ABL (v-abl Abelson murine leukemia viral oncogene 
homolog), ACTB (ß-actin), B2M (ß-2-microglobulin), GUSB (ß-glucuronidase), 
HMBS (hydroxymethyl-bilane synthase), HPRT (hypoxanthine 
phosphoribosyltransferase), RPS7 (ribosomal protein S7), YWHAZ (tryptophan 
5-monooxygenase activation protein, zeta polypeptide). The assays were 
tested together with previously developed TaqMan® assays for feline GAPDH 
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(glyceraldehyde-3-phosphate dehydrogenase) and the universal 18S rRNA 
gene. The suitability of the candidate genes was assessed using the geNorm 
and NormFinder programs. A significant difference was found among the 
expression levels of the ten candidate reference genes (pKW < 0.001): the 
expression levels for the 18S rRNA gene were > 106-times higher than those 
of ABL and HMBS. This will allow matching the expression level of the 
reference genes with that of the target genes. The presence of pseudogenes 
was confirmed for four of the eight tested genes. The study confirmed that 
reference gene expression stability varies considerably among the tested 
feline tissues. No reference gene was suitable for optimal gene expression 
normalization in all tissues. For the majority of the tissues, two to four 
reference genes were found to be a recommendable number of genes for 
accurate normalization. ACTB, RPS7, and ABL were among the most stable 
reference genes in the studied tissues, while HPRT, 18S rRNA gene and 
GAPDH were among the least stable ones. The present study yields essential 
information on the correct choice of feline reference genes depending on the 
tissues analyzed.  
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2 Introduction 
The domestic cat is an important study subject not only in veterinary medicine 
but also in medical research. It plays an essential role as a laboratory model 
for human infectious, hereditary and endocrine diseases and allows the study 
of topics such as host-pathogen interactions, defence mechanisms, and 
development of prophylactic or therapeutic regimens. Of importance in this 
context is not only the feline immunodeficiency virus (FIV), the single naturally 
occurring animal model for HIV-AIDS pathogenesis (11, 37) and the feline 
leukaemia virus (FeLV), an important model for retrovirus and tumor research 
(33, 38), but also other infectious agents, some of them related to fatal human 
infections (2, 37). Furthermore, in the genome of the cat, various mutations 
have been characterised that are associated with genetic diseases, and 280 
phenes have been reported, 136 of which could potentially serve as models for 
human hereditary diseases (http://omia.angis.org.au/). Models under 
investigation include the glycogen storage disease type IV reported in the 
Norwegian Forest cat, the only reported animal model for this pathology (16), 
or the obesity-associated form of diabetes mellitus in the domestic cat that is 
similar to the type 2 diabetes mellitus in humans (50). For the latter, the 
domestic cat presents a valuable model for understanding the molecular 
mechanisms linking obesity to the development of insulin resistance, 
hypertension, and atherosclerosis (50). The potential of the cat as an animal 
model and the similarities in genome organisation between humans and 
felines (35, 36) provide the basis for a wide range of gene expression studies. 
Quantitative real-time PCR assays are the method of choice for reliable and 
fast quantification of transcription levels in gene expression studies, and they 
are used frequently in many areas of modern research. Real-time PCR 
provides quantification of input templates over a broad linear range, low 
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sample consumption, rapid throughput of large sample numbers, and low risk 
of contamination (19, 21, 30). Accurate normalisation is of fundamental 
importance to obtaining sound results. Normalisation is usually achieved by 
simultaneous amplification of reference genes along with the target gene. 
Several publications emphasise the need for more than one reference gene for 
exact analysis of transcription levels (39, 40, 46). When selecting reference 
genes, several critical points should be considered, including a stable, 
experimentally-independent expression pattern of the candidate gene, the 
absence of processed pseudogenes, an adequate level of expression, and a 
lack of potential co-regulation among target and reference genes (22, 41, 43). 
For the domestic cat some potential reference genes have been studied using 
pair-wise correlation analysis (geNorm) (47) and real-time PCR systems based 
mainly on SYBR Green chemistry (9, 24, 25, 39). The SYBR Green principle 
has the advantage that it is less costly; however, TaqMan® systems usually 
have a higher specificity and lead to less non-specific product formation than 
SYBR Green assays. No systematic study using TaqMan® real-time PCR 
assays for potential feline reference genes is available. In addition, no 
comparisons of pair-wise analysis with ANOVA-based methods (NormFinder) 
(1) have been published, and most assays for feline reference genes were 
conducted using pathological samples. Data on tissues from healthy cats are 
largely missing. 
Thus, the purpose of the present study was to i) develop and optimise 
TaqMan® real-time PCR assays for potential feline reference genes and ii) 
evaluate the suitability of these assays for normalisation in the blood and other 
tissues from clinically healthy cats and from neoplastic tissues. The earlier 
tissues were chosen to cover those frequently included in studies investigating 
infectious diseases and immunological, endocrine, metabolic, and 
inflammatory disorders. The neoplastic tissues originated from FeLV-infected 
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cats; the expression of reference genes may differ in neoplastic tissues (22, 
26). For stability comparison of the potential reference genes, two programs 
were used: the ANOVA-based NormFinder and the geNorm, which does pair-
wise calculations. 
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3 Materials and Methods 
3.1 Sample collection 
All domestic cats included in this study had been in experimental studies 
officially approved by the veterinary office of the appropriate Swiss Canton. 
They were kept in groups under optimal ethological conditions. Clinically 
healthy cats were available from negative control groups, and they were 
sacrificed for reasons unrelated to this study. Tissue samples were collected 
upon necropsy from 15 clinically healthy cats (ten neutered males and five 
intact females). They originated from lymphatic tissues including bone marrow 
(n = 11), mesenteric lymph node (n = 10), and spleen (n = 10); from the 
endocrine tissues of the adrenal gland (n = 11), pancreas (n = 13), thyroid (n = 
10), and parathyroid (n = 7); from the gastrointestinal tissues of the parotid 
gland (n = 9), duodenum (n = 10), and ileum (n = 10); and from the brain (n = 
13), myocardium (n = 10), kidney (n = 14), and liver (n = 9). The cats ranged in 
age from 1.25 to 13 years (median age 3.8 years). In addition, EDTA-
anticoagulated whole blood samples were collected from 11 specific pathogen-
free (SPF) cats (five males at the age of 0.5 years, five neutered males at 6 
years, and two spayed females at 14 years). Upon necropsy, neoplastic 
tissues (n = 12, including tissue from liver (1), spleen (2), kidney (2), 
mesenteric lymph node (3), ileum (1), and thymus (3) were collected from six 
FeLV-infected cats (three neutered males, one neutered and two intact 
females; ages of 3 to 13 years). Five of the cats had been diagnosed with 
malignant lymphoma; one had leucosis. All tissues were snap-frozen upon 
collection and stored at -80°C until extraction of nucleic acids. 
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3.2 Nucleic acid extractions 
Tissues (30-35 mg, in duplicate) were homogenised prior to RNA extraction in 
350 µl of RLT buffer (Qiagen, Hombrechtikon, Switzerland) containing 3.5 µl ß-
mercaptoethanol, together with a 5 mm Ø steel bead (Schieritz & Hauenstein, 
Arlesheim, Switzerland) in a Mixer Mill MM 300 (Retsch, Haan, Germany). 
Samples were then processed using the RNeasy Mini Kit (Qiagen) following 
the manufacturer’s recommendations. In a preliminary experiment using 
selected samples (n = 4), the effect of a digestion step on the RNA binding 
silica gel membrane of the spin column, performed according to the 
manufacturer’s instructions with RNase-free DNase, was assessed (on-column 
DNase treatment). In addition, for bone marrow, lymph node, spleen, and 
thyroid samples, the RNeasy Plus Mini Kit (Qiagen) with genomic DNA (gDNA) 
Eliminator spin columns and RLT plus buffer was applied according to the 
manufacturer’s recommendations. The presence of contaminating gDNA was 
assessed using GAPDH quantitative reverse transcriptase (RT-) PCR with a 
minus-reverse transcription control with Reverse Transcriptase qPCR 
Mastermix (Eurogentec, Seraing, Belgium). RNA was extracted from 1 ml of 
blood within 60 minutes of collection using the QIAamp Blood Mini Kit (Qiagen) 
and stored at -80°C until further use. gDNA was extracted using the DNeasy 
Blood & Tissue Kit (Qiagen). For all RNA and DNA extractions, negative 
controls were prepared with each batch. 
 
3.3 First-strand cDNA synthesis 
The RNA yield and the ratio of absorbance at 260 nm to 280 nm (A260/A280 
ratio) were measured using the NanoDrop ND-1000 Spectrophotometer 
(NanoDrop Technologies, Witec, Littau, Switzerland). Samples containing < 
10 ng/µl of RNA were excluded from the study. First-strand cDNA was 
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synthesised in quadruplicate using the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Rotkreuz, Switzerland) according to the 
manufacturer’s instructions. The amount of input RNA in each reaction was 
calculated to be 2 µg. The cDNA GAPDH copy number / RNA GAPDH copy 
number ratio was calculated as a measure of the efficiency of the cDNA 
synthesis; this ratio was used to normalise the reference gene copy numbers 
as assessed by quantitative real-time PCR. 
 
3.4 Development of real-time PCR assays for feline reference genes 
Using Primer Express™ software (versions 2 and 3, Applied Biosystems), 
primers and TaqMan® probes were designed for eight potential reference 
genes: ABL, ACTB, B2M, GUSB, HMBS, HPRT, RPS7, and YWHAZ 
(essential gene-specific data are given in Table 1). The sequences and 
information on gene organisation were retrieved from Ensembl 
(http://www.ensembl.org/index.html), GenBank (http://www.ncbi.nlm.nih.gov) 
and the Genome Annotation Resource Fields (GARFIELD) 
(http://lgd.abcc.ncifcrf.gov) (41). All systems were designed so that the 
predicted amplicons would span exon-exon boundaries (Table 2). The eight 
primer pairs (Microsynth, Balgach, Switzerland) were tested for amplification of 
the appropriate length amplicon using 5 µl of cDNA in a total volume of 25 µl 
per reaction on a Rotor-Gene6000 real-time rotary analyser (Corbett, Mortlake, 
Australia) using the TaqMan® Fast Universal PCR Master Mix (Applied 
Biosystems). Thermocycling conditions consisted of an initial denaturation of 
20 s at 95°C, followed by 45 cycles of 95°C for 3 s and 60°C for 45 s. The 
PCR products were analysed by gel electrophoresis on 3% agarose gels and 
stained with ethidium bromide, and bands were visualised using the 
Chemigenius2 BioImaging System (Syngene, Cambridge, UK).  
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In order to test for potential amplification of pseudogenes or of gDNA, the eight 
primer pairs were also assayed with gDNA under the same conditions. 
Moreover, the possible presence of pseudogenes for the eight assays was 
assessed using the Ensembl Genome Browser. In all PCR assays, water was 
used as a negative control. 
 
3.5 Optimisation of quantitative real-time PCR assays 
After the primers had been tested for correct amplification of the estimated 
amplicon length, the eight newly designed real-time TaqMan® PCR systems 
were optimised using cDNA and a 3 x 3 primer matrix with 50, 300, and 900 
nM end concentrations. Each of the nine conditions was run in quadruplicate 
under the conditions described above. Moreover, using the best primer 
concentration, five different probe (Microsynth) end concentrations (50, 100, 
150, 200, and 250 nM) were tested for optimal performance. The optimised 
assays were tested together with a feline GAPDH TaqMan® real-time PCR 
assay developed previously in our laboratory (28) and a universal 18S rRNA 
gene (Applied Biosystems).  
 
3.6 Production of DNA standards for absolute quantification 
cDNA synthesised from feline tissue samples was used to generate standard 
templates for absolute quantification of ABL, ACTB, B2M, GUSB, HMBS, 
RPS7, and YWHAZ. The corresponding sequences were amplified using 
primers enclosing the TaqMan® real-time PCR sequences under conditions 
described (Table 3) (49). The gel purified amplification products (Gen Elute 
PCR Clean-Up Kit, Sigma-Aldrich, Buchs, Switzerland) were subjected to a 3’ 
A-tailing reaction (Sigma) and ligated into the TOPO TA cloning vector pCRII 
(Invitrogen, Basel, Switzerland), selected by Ampicillin resistance, followed by 
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sequencing (Microsynth). Plasmids were linearised by restriction digestion with 
BamHI (Promega, Wallisellen, Switzerland), SpeI (New England BioLabs, 
Berverly, MA, USA), or KpnI (Roche, Rotkreuz, Switzerland) and then gel 
purified. The copy numbers were calculated based on spectrophotometric 
analysis (NanoDrop ND-1000). Carrier salmon sperm DNA (Invitrogen) at a 
concentration of 30 µg/ml was used for the tenfold serial dilutions of the 
standard templates, and aliquots of the dilutions were stored at -20°C until 
use. For the GAPDH assay, the DNA standard described previously (28) was 
used. For the HPRT and 18S rRNA assays, cDNA from kidney tissue of a 
clinically healthy cat was diluted tenfold in carrier salmon sperm DNA and in 
nuclease free water, respectively, to produce an arbitrary standard. The copy 
numbers of the latter samples were estimated by matching the resulting Ct 
values with those of the feline GAPDH standard. 
 
3.7 Efficiency, sensitivity, linear range and precision of the real-time PCR 
assays 
The efficiency of the newly designed assays was calculated as described (23) 
using the following equation: E = (10(-1/slope))-1. The sensitivity of the seven new 
systems (for which DNA standards had been produced) was determined by an 
endpoint dilution experiment: ten replicates of the dilutions containing 102, 101, 
and 100 standard template copies per reaction, respectively, were tested. The 
sensitivity of the assay is given by the dilution in which at least seven of 10 
replicates are still positive (31). The linear range of amplification and the 
precision of all newly developed TaqMan® real-time PCR assays were 
determined using tenfold serial dilutions of the plasmid or arbitrary standards. 
For the precision analysis, the dilutions were chosen according to the ranges 
of Ct values that were characteristic for the expression levels of the particular 
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reference genes in the tissues. Intra-run (n = 10) and between-run (n = 5) 
analytical performances of the PCR measurements were determined using 
these control materials. 
 
3.8 Data evaluation statistics 
For stability comparison of candidate reference genes, the Microsoft Excel 
Add-in NormFinder (1) was applied. Comparisons were made with calculations 
performed using the geNorm version 3.4 (48). The NormFinder uses an 
ANOVA-based model (1), while the geNorm calculates the stability using a 
pairwise comparison model (48). In addition, the geNorm ranks candidate 
reference genes according to the average expression stability, M (48). Genes 
with the lowest M values have the most stable expression; a cut-off of 1.5 was 
proposed, above which the variation is assumed to be too high for accurate 
normalisation (48). Moreover, the optimal number of reference genes required 
for accurate normalisation was estimated using the geNorm. To this end, the 
pairwise variation Vn/n+1 between sequential normalisation factors containing 
an increasing number of reference genes was calculated. If Vn/n+1 < 0.15, the 
recommended number of reference genes is given by n; the inclusion of an 
additional reference gene is not required (48).  
Statistical analyses were performed with GraphPad Prism for Windows, 
Version 4.03 (GraphPad software, San Diego, CA). Expression levels of 
individual genes in different tissues were tested for statistical differences 
among several groups using the non-parametric Kruskal-Wallis test (pKW) and 
the Dunn's Multiple Comparison Test (pD). The expression levels of different 
genes in individual samples were tested for statistical differences between two 
groups using the non-parametric Wilcoxon signed rank test for paired samples 
(pW) and among several groups using the non-parametric Friedman test for 
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paired samples (pF) and the Dunn's Multiple Comparison Test (pD). P-values 
< 0.05 were considered significantly different. 
 
Results 
3.9 RNA extractions and gDNA contamination 
RNA extractions from blood using the QIAamp Blood Mini Kit and from tissues 
using the RNeasy Mini Kit yielded RNA with a low level of contaminating gDNA 
(<1%), with the exceptions of bone marrow, lymph node, spleen, and thyroid. 
When RNA extraction was performed for these four tissues using the RNeasy 
Plus Mini Kit, contaminating gDNA levels were < 1%. These additionally 
processed RNA samples were used for analysis of these four tissues. No on-
column DNase treatment was used in the main experiment because the loss of 
RNA due to DNase treatment was > 90%, as determined in a preliminary 
experiment (data not shown). RNA purity was estimated from A260/A280 ratio; 
this ratio ranged from 1.7 to 2.1. 
 
3.10 Evaluation of the primer pairs 
When the primers were tested in a conventional PCR with cDNA, all assays 
yielded PCR products of the predicted size (Table 2). The primers were then 
assessed using the same procedure and gDNA to test for the amplification of 
gDNA and the possible presence of pseudogenes. Bands of the size of the 
cDNA were found for ACTB, HPRT, RPS7, and YWHAZ, indicating the 
presence of processed pseudogenes for these genes, but not for ABL, B2M, 
HMBS, and GUSB (Table 2). This was consistent with the results retrieved 
from Ensembl. In addition, for ACTB, GUSB, and HMBS, PCR products 
presumably of the size of the gDNA, including the introns, were detected 
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(Table 2). For ACTB, it was shorter (~400 bp) than calculated from an 
alignment of the human with the feline sequence (568 bp, Table 2). 
 
3.11 Evaluation and optimisation of the newly developed real-time PCR 
assays 
Primer and probe concentrations for the eight newly designed TaqMan® real-
time PCR assays were optimised using cDNA (for final concentrations see 
Table 4). When the real-time TaqMan® PCR assays were tested using gDNA 
instead of cDNA, specific amplification was found for ACTB, HPRT, RPS7, and 
YWHAZ, confirming the presence of pseudogenes (Table 2). In addition, 
amplification was detected for GUSB (Table 2). 
 
3.12 Efficiency, sensitivity, linear range and precision of the real-time 
PCR assays 
The amplification efficiencies of the eight newly designed assays and the feline 
GAPDH real-time PCR were ≥ 96%. The lower detection limit of the assays for 
ABL, ACTB, B2M, GUSB, RPS7, and YWHAZ was equal to one copy of target 
standard plasmid per reaction in an endpoint dilution experiment (7 to 10 out of 
10 reactions positive). For HMBS the lower limit of detection was found to be < 
100 copies per reaction (10 out of 10 reactions positive). For all newly 
developed TaqMan® real-time PCR assays, we observed linearity of the assay 
over a ≥108-fold range. The coefficients of variation ranged from 0.44% (B2M) 
to 1.18% (YWHAZ) for the intra-run precision analysis and from 0.49% (ACTB) 
to 2.15% (HMBS) for the between-run analysis. 
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3.13 Expression levels of candidate reference genes 
Transcription of the ten candidate reference genes was detectable above 
background in all tissue and blood samples from all cats tested. The potential 
reference genes were classified into three groups according to their 
transcription levels (all healthy tissues and blood samples were included in the 
analysis; Figure 1a). The difference in median expression levels was found to 
be 106 between the most abundant and least abundant transcripts: 18S rRNA 
showed a high transcription level (median copy number/reaction ~109); ACTB, 
GAPDH, B2M, HPRT, and RPS7 were found to have intermediate transcription 
levels (median copy number/reaction 2.6x104 to 9.3x104), and ABL, GUSB, 
and HMBS had low transcription levels (median copy number/reaction 0.5x103 
to 1.9x103; Figure 1a). YWHAZ had a transcription level between the 
intermediate and low levels (median copy number/reaction 6.9x103). Individual 
candidate reference genes had different expression levels across all studied 
tissues; the transcription levels differed significantly among all different 
reference genes when all tissues were included in the analysis (pF < 0.0001; 
pD < 0.05), with the exceptions of ACTB, GAPDH and B2M; GUSB and 
HMBS; and HPRT and RPS7 (Figure 1a). The latter three groups of reference 
genes did not have significantly different transcription levels (pD > 0.05; Figure 
1a). A reference gene transcription level pattern similar to that seen in all 
tissues combined was found when individual tissues were examined (for a 
representative example, see Figure 1b), with some particular exceptions. In 
the bone marrow samples HMBS transcription was significantly higher than 
GUSB transcription (pW = 0.0010; Figure 1c), in the myocardium and brain 
samples GAPDH transcription was significantly higher than B2M transcription 
(pW = 0.0020; Figure 1d and 1e), in the blood B2M and ACTB transcription 
levels were higher than GAPDH transcription (pW = 0.0039; Figure 1f), and in 
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the liver YWHAZ was significantly lower than RPS7 and HPRT (pW = 0.0039, 
data not shown).  
When expression levels of the individual potential reference genes were 
analysed among different tissues some significant differences were found. The 
most prominent were the following: GAPDH was significantly higher in the 
myocardium, brain, and blood samples than in most of the other tested tissues 
(pKW < 0.0001; pD < 0.001 for 11 of the other tested tissues; Figure 2a); ABL 
was significantly lower in the bone marrow samples than in the majority of the 
other tested tissues (pKW < 0.0001; pD < 0.001 for eight of the other tested 
tissues; Figure 2b), B2M was higher in the blood samples (pKW < 0.0001; pD 
< 0.001 for twelve of the other tested tissues; Figure 2c), and YWHAZ was 
higher in the blood and brain samples than in the majority of the other tissue 
samples (pKW < 0.0001; pD < 0.001 for 11 and 12, respectively, of the other 
tested tissues; Figure 2d). No particular differences in expression levels were 
observed when the neoplastic tissues were compared to the healthy tissues 
(pW > 0.05 for all genes tested). 
 
3.14 Expression stability of candidate reference genes in different 
tissues 
The stability of reference gene expression was estimated based on the 
calculations of the geNorm and NormFinder software, and the rank order given 
by the two programs differed significantly (Table 5; for details see also 
Appendix). However, some agreement was found between the NormFinder 
results and the results according to the M values of the geNorm program 
(Table 5); for three tissues (bone marrow, duodenum, and kidney) the rank 
order was identical. The two genes that ranked best were identical with both 
methods (manual M value ranking and NormFinder) for the majority of the 
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tissues except for lymph node, parotid gland, liver, and blood samples. All 
further stability analyses were made using the NormFinder results.  
The stability of the genes varied considerably depending on the tissues tested. 
When tissues were analysed individually, no single gene was found among the 
three best-ranked genes in all of the tested tissues. In 11 of the 14 healthy 
tissues, RPS7 ranked among the three most stable genes, followed by ACTB 
in eight and ABL in six out of 14 tissues (Table 5). Somewhat less stable were 
GUSB and YWHAZ; they were among the most stable genes in five of the 14 
tissues used. GAPDH was among the three most stable genes in the 
NormFinder ranking in four out of 14 tissues. HMBS, B2M, HPRT, and 18S 
rRNA were found to be the least stable, HMBS with two, B2M and HPRT with 
one, and 18S rRNA with no rankings among the most stable genes in the 14 
tissues tested. When all 14 healthy tissues were included at once in the 
analysis (Table 5), RPS7, GUSB, and YWHAZ ranked as the best three 
reference genes, while ABL and ACTB ranked fourth and fifth. Some particular 
differences were found in certain healthy tissues; RPS7, which ranked first 
overall, was found to be less stable in the ileum, lymph node, and thyroid 
samples. Moreover, ACTB ranked last in the pancreas samples (Table 5). In 
the blood samples, GAPDH and B2M ranked better than in other tissues, but 
RPS7 ranked only second to last (Table 5). Remarkably, in the neoplastic 
tissues the two most stable genes were identical to those in all the healthy 
tissues (RPS7 and ACTB). ABL, GUSB, and YWHAZ were found to be less 
stable than in the healthy tissues (Table 5). 
 
3.15 Number of reference genes for optimal normalisation 
The optimal number of reference genes for normalisation was calculated using 
the geNorm program. The number of recommended reference genes for 
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optimal normalisation varied considerably depending on the tissue being 
tested. For brain, myocardium, lymph node, and adrenal gland the pairwise 
variation V2/3 was ≤ the proposed cut-off of 0.15 (Appendix); therefore, two 
reference genes should be sufficient for accurate normalisation in those 
tissues. Similarly, for parathyroid, parotid gland, liver and kidney, three; for 
thyroid, four; for spleen and neoplastic tissues, five; and for blood, seven 
reference genes were found to be necessary for accurate normalisation 
according to the geNorm program (Appendix). For four tissues the pairwise 
variation V always exceeded the cut-off of 0.15. The recommended number of 
reference genes for these four tissues (lowest V value) was: five for the 
pancreas, six for ileum and bone marrow, and seven for the duodenum 
(Appendix). For all tissues combined, the optimal number of reference genes 
that would have been necessary for normalisation exceeded ten using the 
reference genes tested in this study. For the three tissue groups, endocrine, 
lymphatic, and gastro-intestinal tissues, the V value always exceeded the cut-
off of 0.15; the recommended number of reference genes for these tissue 
groups (lowest V value) was found to be six (Appendix).  
 
3.16 Normalisation 
When tissues were analysed individually, a normalisation factor was calculated 
for all tissues with the exception of the pancreas. For the latter, all M values 
calculated by geNorm exceeded the proposed cut-off value of 1.5, and no 
normalisation factors based on the geometric mean of multiple reference 
genes could be computed (Appendix 1). When tissue groups were analysed, a 
normalisation factor was calculated for the endocrine and gastrointestinal 
tissues but not for the lymphatic group. No normalisation factor was calculated 
for all tissues combined. 
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4 Discussion 
The present study is the first to develop and evaluate real-time TaqMan® 
assays for the quantification of a series of potential feline reference genes. 
The assays were applied using feline peripheral blood and tissue samples 
from healthy cats. The latter were chosen based on their applicability in 
research areas such as the investigation of immune functions or metabolism, 
characterisation of infections, inflammatory reactions, or excretion patterns of 
pathogens. In this regard, the selected tissue categories also met the claim of 
suitability regarding their potential use in animal models for several human 
diseases. The expression stability of potential reference genes was analysed 
and compared for the feline species for the first time using pair-wise and 
ANOVA-based analyses. Remarkable differences concerning gene expression 
stability were found among the different tissues using the different analysis 
methods. 
We selected ten commonly used mammalian reference genes featuring a 
broad range of cellular functions (Table 1) in order to reduce the risk of co-
regulation among the target and reference genes. Moreover, recently it was 
reported that nine of the ten genes included in this study, i.e., ACTB, ABL, 
B2M, GAPDH, GUSB, HMBS, HPRT, YWHAZ, and the 18S rRNA gene, are 
assumed not to be co-regulated (20, 32, 48). 
When selecting potential reference genes, another issue that needs to be 
considered is the presence of processed pseudogenes, which are known to 
hamper data interpretation in mRNA transcription analysis (17, 51). We 
therefore included candidate reference genes that are known to lack 
pseudogenes in humans, i.e., ABL, B2M, GUSB, and HMBS (29, 51). When 
we tested these four genes in felines, we confirmed that they also lack 
pseudogenes in the cat (at least for the sequences included in our assays). 
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For the other four newly developed assays (ACTB, HPRT, RPS7, and 
YWHAZ), we demonstrated the presence of processed pseudogenes within 
the sequences targeted by our assays. For feline GAPDH the presence of one 
copy of a pseudogene had been reported earlier (34). To minimise co-
amplification of pseudogenes, gDNA contamination of the assayed RNA must 
be controlled. In the present study, gDNA contamination was reduced to a 
minimum (< 1% of the RNA) by choosing the optimal RNA extraction method 
for each tissue. The inclusion of a DNase digestion step was omitted because 
we found it to significantly reduce the RNA yield (> 90% loss). The absence of 
a DNase treatment and thus the presence of sufficient amounts of RNA might 
explain why we always had PCR signals clearly above background for all 
samples in the present study, in contrast to some other reports in which HPRT, 
ABL, or HMBS could not (reliably) be detected (42, 50). 
Another method for reducing the possible interference of gDNA - including 
conventional but not processed pseudogenes - with the RNA under 
investigation in gene expression studies is the positioning of the real-time PCR 
target on exon-exon junctions. In the present study, all eight newly developed 
assays were designed to span such a junction. The assays for those four 
potential reference genes lacking processed pseudogenes did not amplify 
gDNA, with the exception of GUSB. For the latter, the amplicon size from 
gDNA was only 532 bp due to a short intron and the primer design software 
had positioned the exon-exon junction only three nucleotides before the 3’ end 
of the probe (Table 2). 
The expression level of an ideal reference gene should not undergo tissue-
specific and experimental-dependent variation and should be similar to that of 
the target genes (7, 22, 42, 44, 46, 48). We measured the RNA transcription 
levels of the ten selected candidate reference genes in blood samples and 15 
different tissues from cats. While the expression levels among the reference 
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genes differed considerably, most of them were within a range that could be 
used for proper normalisation of many target genes. Only the 18S rRNA gene 
expression level was found to be impracticably high compared to that of most 
target genes. Significant differences were found when the expression levels of 
the potential reference genes were analysed in different tissues. GAPDH 
expression was higher in brain, myocardium, and blood samples; this is 
consistent with results reported for human tissues (3, 48). Tissue-specific 
expression differences could also be detected for B2M, where expression was 
significantly higher in blood. This has also been demonstrated for human 
leukocytes, where a significantly higher expression level was found (48). 
We then calculated the expression stability of the tested reference genes using 
the NormFinder and compared it to that calculated by the geNorm software, as 
well as to a stability ranking performed manually using the M values allocated 
to the individual genes by the geNorm program. The reference gene rankings 
automatically produced by the two programs were remarkably different. Better 
agreement was found between the ranking provided by the NormFinder and 
the manual ranking according to the M values of the geNorm. Consequently, 
and intriguingly, differences were observed in the automatically calculated 
geNorm gene ranking and the ranking performed manually using the M values 
of the geNorm program. To our knowledge this has not been observed 
previously.  
In general, when comparing results of the NormFinder and the geNorm, the 
underlying mathematical models need to be considered. The pairwise 
comparison model of the geNorm program provides a combination of two 
genes whose expressions are most correlated in the tested sample by 
stepwise exclusion of the genes with the highest M values (48). The stability 
measure M calculated by the program is defined as the pairwise variation 
between a gene and all the other genes (48). We primarily assessed the 
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ranking provided by the NormFinder program. In the geNorm program co-
regulated genes that show a tendency towards similar expression profiles may 
become highly ranked independent of their expression stabilities (1). On the 
other hand, the ANOVA-based model of the NormFinder program selects the 
highest ranked gene based on the highest expression stability due to minimal 
estimated intra- and intergroup variation (1). This approach is not significantly 
affected by co-regulation of candidate reference genes (1). Although we had 
aimed to avoid including reference genes that are co-regulated (see above), 
the differences found between the results of the two programs using different 
mathematical models might indicate that some of the genes were still co-
regulated. 
Studies of the validation of reference gene expression have been performed 
for different mammalian species including humans (4, 29, 42, 48), companion 
animals (6, 12, 39, 40), farm animals (13, 14, 18, 43), and horses (5, 8). No 
general best reference gene has been found for all species. Moreover, our 
results demonstrated that in the cat the expression stability of the ten 
investigated reference genes differed significantly depending on the tested 
tissues. No single gene was found to be suitable for accurate normalisation in 
all investigated tissues within one species. Our findings are consistent with the 
results reported from other mammalian species (7, 27, 42, 46) and highlight 
the need for proper validation of reference genes in the respective tissues 
preceding any experimental set-up. It has been demonstrated that 
normalisation of data sets with different reference genes, such as GAPDH and 
ACTB, may influence the outcome of the study; the expression profiles of 
target genes were markedly influenced and statistically significant differences 
between study groups were present or absent depending on the choice of the 
reference genes (10, 15, 45). 
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In the present study, in the majority of the examined healthy tissues, RPS7, 
ACTB, and ABL were among the most stably expressed genes. When all 
healthy tissues were combined for analysis, the three most stable genes were 
found to be RPS7, GUSB, and YWHAZ. These results are only partially in 
agreement with those of a recent validation of feline reference genes using 
SYBR Green real-time PCR assays and pairwise analysis (39). In the latter 
study, RPS7 was also found as the most stable gene in six tissues under 
investigation; YWHAZ ranked fourth (after two ribosomal protein genes not 
included in the present study), and GUSB was found among the least stable 
genes; ACTB and ABL were not examined (39). Three feline tissues were 
included in both the previous (39) and the present study. While for the kidney 
at least some agreement was found in the gene ranking (RPS7 and YWHAZ 
were among the stable ones; HPRT and GAPDH were rather unstable), the 
results for liver and myocardium differed significantly. The observed 
differences could be (apart from the differences in the applied methods) due to 
the fact that while we examined tissues from clinically healthy cats, Penning 
and co-workers (39) studied tissues from sick cats. They included liver, heart, 
and kidney samples from cats with hepatocellular carcinoma, hepatitis, cardiac 
hypertrophy, chronic kidney failure, and kidney tumours (39). Gene expression 
studies frequently examine pathological tissues and compare them with 
healthy tissues. The present results emphasise the need to include samples 
from healthy tissues in the evaluation of suitable reference genes for correct 
normalisation and comparison of healthy to pathological tissues. We suggest 
choosing the reference gene according to its suitability in the healthy tissue of 
the particular species (e.g., the present study of the cat) and then evaluating it 
in the pathological tissues of interest in a preliminary experiment. Furthermore, 
the number of samples under evaluation might influence the study outcomes: 
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we intended to include 10 samples per tissue, while in the previous study, for 
the majority of the tissues, fewer samples were available (39). 
Some particular differences in the reference gene stability were observed in 
the present study. Although B2M in general was not a very stable reference 
gene, it ranked second to fourth in stability in the blood samples. This would 
confirm a finding in human blood cells, where B2M seemed a good choice for 
normalisation in leukocytes, while it was one of the least stable genes in 
tissues (48). For the neoplastic tissues, only a limited number of samples from 
FeLV-infected cats with malignant lymphoma and leucosis were available, and 
they originated from different tissues. Nonetheless, it is remarkable to note that 
the expression levels of the chosen reference genes did not differ significantly 
from those in the healthy tissues. In addition, the two most stable genes in the 
neoplastic tissues were identical to those in the investigated healthy tissues, 
although overall some differences were found in the stability ranking of the 
potential reference genes. Thus, two genes (RPS7 and ACTB) could serve as 
a good first choice to be tested in these neoplastic tissues as well in future 
studies.  
We calculated the minimum number of reference genes necessary for 
accurate normalisation using the geNorm program (48). Applying the proposed 
cut-off value of 0.15 for the pairwise variation Vn/n+1 (48), two to three reference 
genes were required for accurate normalisation in most tissues. Moreover, for 
all tissues except the pancreas, the lymphatic tissue group, and all tissues 
combined, a normalisation factor was calculated. According to Vandesompele 
and co-workers, using the three best reference genes is a valid normalisation 
strategy in most cases; it results in much more accurate and reliable 
normalisation than the use of only one reference gene does (48). In addition, 
practical and financial considerations may support the use of a limited number 
of reference genes. This strategy is supported by the finding that no significant 
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effect on the relative quantity of the target gene expression was demonstrated 
when using the combination of the two best genes compared to using five of 
the six most stable genes (32). 
From our results, we recommend consulting the literature for appropriate 
reference genes according to the tissues and species under investigation. The 
reference genes should be examined in healthy individuals. If the 
corresponding data is not available, preliminary experiments for the 
identification of optimal reference genes are necessary. If this is impossible, 
we recommend using RPS7 as the primary choice for a reference gene in 
feline tissues (with tissue-specific limitations documented in the present study); 
results should be confirmed using other reference genes, such as ACTB, ABL, 
and/or YWHAZ. 
In this study, we investigated for the first time the most reliable feline reference 
genes for normalisation of gene expression data in blood samples and 15 
different tissues, including endocrine, lymphatic, and gastrointestinal tissues, 
using real-time TaqMan® PCR assays and pair-wise and ANOVA-based 
analyses. Our results indicated that stability of the reference genes varies 
among the different tissues, and no gene was found among the most stable 
ones for all the tissues under investigation. Moreover, significant differences 
were found using either pair-wise or ANOVA-based analysis approaches. The 
three most stable genes were found to be RPS7, ACTB, and ABL, while B2M, 
HPRT, and the 18S rRNA gene were the least stable ones. The frequently 
used GAPDH had an acceptable stability in only a few tissues. These data 
emphasise the need for proper validation of candidate reference genes in the 
respective tissues and species in healthy individuals preceding the initiation of 
any experimental gene expression study. 
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FIGURE 1. Expression levels of candidate reference genes in different tissues. 
a) All healthy tissues combined, b) adrenal gland, c) bone marrow, d) 
myocardium, e) brain, and f) blood samples. Values are given as copy 
numbers per PCR. For the 18S rRNA gene and HPRT the copy numbers were 
calculated using an arbitrary standard (see M&M). Data are shown as 
boxplots. Boxes extend from the 25th to the 75th percentile; a horizontal line 
represents the median, and the error bars extend down to the smallest and up 
to the largest value. Expression levels were analyzed for statistical differences 
using the Friedman test (pF-values as indicated in the figure). Significant 
differences between two particular genes were analyzed by the Wilcoxon test 
for paired samples (asterisks and circles, respectively, mark statistically 
significant differences between two genes; pW ≤ 0.0039). 
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FIGURE 2. Expression levels of selected reference genes in individual tissues. 
a) GAPDH, b) ABL, c) B2M, and d) YWHAZ. Values are given as copy 
numbers per PCR. Data are shown as boxplots. Boxes extend from the 25th to 
the 75th percentile; a horizontal line represents the median, and the error bars 
extend down to the smallest and up to the largest value. Expression levels 
were tested for statistical differences by the Kruskal-Wallis test (pKW-values 
as indicated in the figure) and the Dunn’s post test (asterisks indicate 
statistically significant differences; pD < 0.001). 
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TABLE 1. Specifications of the tested potential feline reference genes. 
Gene Name Function Accession Number 
ABL v-abl Abelson murine 
leukaemia viral oncogene 
homolog 
Protein kinase; regulation of 
cell cycle, mismatch repair, 
DNA damage response 
ENSFCAT000000053061 
ACTB ß-actin Cytoskeletal structural protein AB051104.12 
B2M ß-2-microglobulin Major histocompatibility 
complex antigen class I 
receptor activity 
NM_0010098762  
GAPDH Glyceraldehyde-3-
phosphate 
dehydrogenase 
Glycolytic enzyme AF0971772 
GUSB ß-glucuronidase Glycoside hydrolase 
(carbohydrate metabolism) 
NM_0010093102 
HMBS Hydroxymethyl-bilane 
synthase    
Alias: Porphobilinogen 
deaminase (PBGD) 
Heme synthesis, porphyrin 
metabolism 
ENSFCAG000000011601
HPRT Hypoxanthine 
phosphoribosyltransferase 
Purine synthesis in salvage 
pathway 
EF4536972 
RPS7 Ribosomal protein S7 Ribosomal protein NM_0010098322 
YWHAZ Tyrosine 3-
monooxygenase  
Alias: tryptophan 5-
monooxygenase 
activation protein, zeta 
polypeptide  
Alias: Phospholipase A2 
Mediator of signal transduction 
 
EF4586212 
18S rRNA    Ribosomal RNA X032052 
1 Ensembl, 2 GenBank 
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TABLE 2. Details of Taqman® real-time PCR assays. 
Gene  Oligo Sequence Amplicon 
size (bp)
Genomic 
position (exon) 
Genomic 
(bp) 
Detection  
gDNA 
Pseudo
-gene 
ABL Forward TGTGGCGAGTGGTGATAATACAC 83 2 ~12,000 7 No No 
 Probe CAGCATCACTAAAGGTGAAAAGCTACGAGTCCTT 2 2/3   
 Reverse  TCCACTCACCATTCTGGTTGTAA 3   
ACTB Forward CAACCGTGAGAAGATGACTCAGA 127 3/4 568 8 (Yes) 11 Yes 
 Probe TCTCTGTACGCTTCTGGCCGCACC 3 4   
 Reverse  CCCAGAGTCCATGACAATACCA 4   
B2M Forward CGCGTTTTGTGGTCTTGGT 84 1 3,270 7 No No 
 Probe CGGACTGCTCTATCTGTCCCACCTGGA 2 1   
 Reverse  AAACCTGAACCTTTGGAGAATGC 1/2   
GAPDH Forward GCCATCAATGACCCCTTCAT 82 1 NA (Yes) 11,12 Yes 
 Probe CTCAACTACATGGTCTACATGTTCCAGTATGATTCCA 4 1/2   
 Reverse  GCCGTGGAATTTGCCGT 2   
GUSB Forward CTACATCGATGACATCACCATCAG 80 4 532 9 Yes No 
 Probe ACCAGCGTGAACCAAGACACTGGGC 3 4/5   
 Reverse  CGCCTTCAACAAAAATCTGGTAA 5   
HMBS Forward TGGCAGTGCTGAAAGCCTTA 94 3 554 7 No No 
 Probe TTGAAATCGTTGCTATGTCCACCACAGG 2 3/4   
 Reverse  TTAGAGAGCGCAGTATCAAGAATCTT 4   
HPRT Forward AACTGGAAAGAATGTCTTGATTGTTG 100 4/5 >90,000 7 (Yes) 11 Yes 
 Probe CACTGGCAAAACAATGCAAACCTTGCTTT 3 6   
 Reverse  GACCATCTTTGGATTATACTGCTTGA 6   
RPS7 Forward GTCCCAGAAGCCGCACTTT 74 4/5 ~2,200 10 (Yes) 11 Yes 
 Probe CGCCGTGCACGACGCGA 5 5   
 Reverse  CACAATCTCGCTCGGGAAAA 5   
YWHAZ Forward ACAAAGACAGCACGCTAATAATGC 83 4 2,878 7 (Yes) 11 Yes 
 Probe ATTACTGAGAGACAACTTGACATTGTGGACATC 3 4/5   
 Reverse  CTTCAGCTTCATCTCCTTGGGTAT 5   
18S rRNA 1 Forward CGGCTACCACATCCAAGGAA NA NA NA NT NT 
 Probe TGCTGGCACCAGACTTGCCCTC 6 NA   
 Reverse  GCTGGAATTACCGCGGCT NA   
1 TaqMan® Gene Expression Assay (Applied Biosystems); 2  5' FAM/3' BHQ-1; 3  5' Yakima Yellow/3' BHQ-1; 4 5' FAM/3' TAMRA; 5  5' TET/3' TAMRA; 6 5' VIC/3' MGB; 
7 Ensembl; 8 According to alignments of human and feline sequences retrieved from PubMed; 9 According to the Genome Annotation Resource Fields (GARFIELD) 
(http://lgd.abcc.ncifcrf.gov) (41); 10 According to Penning et al. (39); 11 Amplification of processed pseudogene; 12 According to Leutenegger et al. (28); NA = Not 
available; NT = Not tested
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TABLE 3. Primers used for production of standard templates. 
Gene 
Forward Primer   
Sequences 
Annealing 
temperature 
(°C) 
Amplification 
product (bp) Reverse Primer 
ABL fABL_StdF GGCTTTGAGGGAGACAAGAC 62 402 
 fABL_StdR GAAGCTGCCATTGATCAGAC   
ACTB fACTB_StdF CCATCGAACACGGCATTGTCAC 58 431 
 fACTB_StdR CTTGATGTCACGCACAATTTCCCG   
B2M fB2M-F GGCGCGTTTTGTGGTCTTGGTC 63 339 
 fB2M-R CACTTAACGACCTTGGGCTC   
GUSB fGUSB_StdF GCCGCATTACCATTGCCATCAAC 64 384 
 fGUSB_StdR GCATCAGGTATGGCCACCAGAG   
HMBS fHMBS_StdF CAGCCCAAAGATGAGAGTGATTCG 64 339 
 fHMBS_StdR GGGTGAAAGACAACGGCATCATAG   
RPS7 fRPS7-F AGCTGAGGGAGCTGAACATC 65 432 
 fRPS7-R TGCCCGTGAGCTTCTTATAG   
YWHAZ fYWHAZ_StdF GAGGTTGCTGCTGGTGATGAC  64 329 
  fYWHAZ_StdR CCTGCTTCAGCTTCATCTCCTTGG    
 
TABLE 4. Optimal final concentration of primers and probe for the newly 
designed real-time PCR assays 
 Real-time PCR assay 
 
Forward Primer
(nM) 
Reverse Primer
(nM) 
Probe 
(nM) 
ABL 300 900 50 
ACTB 900 900 50 
B2M 300 900 100 
GUSB 900 300 100 
HMBS 900 900 250 
HPRT 900 900 50 
RPS7 50 900 200 
YWHAZ 900 900 150 
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TABLE 5. Ranking of potential reference genes according to the expression 
stability. The expression stability is given as stability values calculated by 
NormFinder (NF), M values calculated by geNorm (gN(M)), and geNorm 
calculations (gN). Rankings are shown from most (left) to least (right) stable 
genes. 
Tissues Analsysis Ranking 
All endocrine 
tissues tested 
NF 
gN(M) 
gN 
YWHAZ > GUSB > B2M > RPS7> HMBS > ABL > 18S > GAPDH > ACTB > HPRT 
B2M > GUSB > YWHAZ > HMBS > RPS7 > ABL > 18S > GAPDH > ACTB > HPRT 
B2M = HMBS > GUSB > YWHAZ > RPS7 > ABL > 18S > GAPDH > ACTB > HPRT 
  Adrenal  
  gland 
 
NF 
gN(M) 
gN 
HPRT > RPS7 > ABL > B2M > ACTB > GAPDH > 18S > HMBS > YWHAZ > GUSB 
HPRT > RPS7 > ABL > ACTB > B2M > 18S = GAPDH > HMBS > YWHAZ > GUSB  
GAPDH = 18S > RPS7 > HPRT > YWHAZ > ABL > B2M > ACTB > HMBS > GUSB 
  Pancreas 
 
 
NF 
gN(M) 
gN 
RPS7 > GUSB > YWHAZ > HMBS > B2M > GAPDH > ABL > 18S > HPRT > ACTB  
RPS7 > GUSB > YWHAZ > B2M > HMBS > ABL > GAPDH > 18S > HPRT > ACTB  
GUSB = RPS7 > YWHAZ > HMBS > B2M > ABL > 18S > GAPDH > HPRT > ACTB 
  Parathyroid 
 
 
NF 
gN(M) 
gN 
ACTB > RPS7 > GAPDH > HMBS > YWHAZ > ABL > B2M > GUSB > 18S > HPRT 
ACTB > RPS7 > GAPDH > ABL > HMBS > YWHAZ > B2M > GUSB > 18S > HPRT  
GAPDH = RPS7 > ACTB > HMBS > ABL > YWHAZ > B2M > GUSB > 18S > HPRT 
  Thyroid 
 
 
NF 
gN(M) 
gN 
GUSB > ACTB > YWHAZ > HMBS > B2M > RPS7 > ABL > 18S > GAPDH > HPRT 
ACTB > GUSB > YWHAZ > B2M > HMBS > RPS7 > ABL > 18S > GAPDH > HPRT  
ACTB = HMBS > GUSB > B2M > YWHAZ > RPS7 > ABL > 18S > GAPDH > HPRT 
All lymphoid 
tissues tested 
NF 
gN(M) 
gN 
RPS7 > GUSB > ACTB > YWHAZ > ABL > GAPDH > B2M > HPRT > 18S > HMBS 
GUSB > RPS7 > ACTB > YWHAZ > ABL > B2M > GAPDH > HPRT > 18S > HMBS 
GUSB = RPS7 > ACTB > YWHAZ > ABL > B2M > GAPDH > HPRT > 18S > HMBS 
  Bone marrow 
 
 
NF 
gN(M) 
gN 
RPS7 > HMBS > ABL > GUSB > YWHAZ > ACTB > B2M > 18S > HPRT > GAPDH 
RPS7 > HMBS > ABL > GUSB > YWHAZ > ACTB > B2M > 18S > HPRT > GAPDH 
ACTB = YWHAZ > HMBS > GUSB > RPS7 > ABL > B2M > 18S > HPRT > GAPDH 
  Lymph node 
 
 
NF 
gN(M) 
gN 
GUSB > ACTB > B2M > HMBS > YWHAZ > ABL > RPS7 > GAPDH > 18S > HPRT 
GUSB > B2M > ACTB > YWHAZ > ABL > HMBS > RPS7 > GAPDH > 18S > HPRT 
ABL = B2M > YWHAZ > ACTB > GUSB > HMBS > GAPDH > RPS7 > 18S > HPRT 
  Spleen 
 
 
NF 
gN(M) 
gN 
GUSB > RPS7 > ACTB > ABL > B2M > HMBS > YWHAZ > HPRT > GAPDH > 18S 
GUSB > RPS7 > ACTB > B2M > ABL > HMBS > YWHAZ > HPRT > GAPDH > 18S 
ACTB = B2M > GUSB > RPS7 > ABL > HMBS > YWHAZ > HPRT > GAPDH > 18S 
All gastrointest-
inal tissues 
tested 
NF 
gN(M) 
gN 
ACTB > HMBS > YWHAZ > RPS7 > ABL > GAPDH > GUSB > B2M > 18S > HPRT 
ACTB > HMBS > YWHAZ > RPS7 > ABL > GAPDH > GUSB > B2M > 18S > HPRT 
ABL = HMBS > RPS7 > ACTB > YWHAZ > GAPDH > B2M > GUSB > 18S > HPRT 
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  Parotid  
  gland 
NF 
gN(M) 
gN 
ABL > ACTB > RPS7 > YWHAZ > HMBS > B2M > HPRT > GAPDH > GUSB > 18S 
ABL > RPS7 > ACTB > YWHAZ > HMBS > B2M > HPRT > GAPDH > GUSB > 18S 
ABL = ACTB > HMBS > RPS7 > YWHAZ > B2M > HPRT > GAPDH > GUSB > 18S 
  Duodenum 
 
 
NF 
gN(M) 
gN 
RPS7 > GAPDH > ACTB > HMBS > YWHAZ > ABL > 18S > GUSB > B2M > HPRT 
RPS7 > GAPDH > ACTB > HMBS > YWHAZ > ABL > 18S > GUSB > B2M > HPRT 
ACTB = HMBS > RPS7 > GAPDH > YWHAZ > ABL > 18S > GUSB > B2M > HPRT 
  Ileum 
 
 
NF 
gN(M) 
gN 
HMBS > ABL > YWHAZ > ACTB > GAPDH > GUSB > RPS7 > HPRT > B2M > 18S 
HMBS > ABL > ACTB > YWHAZ > GAPDH > GUSB > RPS7 > HPRT > B2M > 18S 
YWHAZ = ACTB > HMBS > ABL > GUSB > GAPDH > RPS7 > HPRT > B2M > 18S 
  Liver 
 
 
NF 
gN(M) 
gN 
GUSB > GAPDH > RPS7 > HPRT > HMBS > YWHAZ > ABL > ACTB > B2M > 18S 
GAPDH > HMBS > HPRT > GUSB > RPS7 > YWHAZ > ABL > ACTB > B2M > 18S 
ACTB = HMBS > ABL > GAPDH > HPRT > GUSB > YWHAZ > RPS7 > B2M > 18S 
  Kidney 
 
 
NF 
gN(M) 
gN 
YWHAZ > RPS7 > ABL > ACTB > HMBS > GUSB > GAPDH > B2M > HPRT > 18S 
YWHAZ > RPS7 > ABL > ACTB > HMBS > GUSB > GAPDH > B2M > HPRT > 18S 
RPS7 = YWHAZ > ABL > ACTB > HMBS > GAPDH > GUSB > B2M > HPRT > 18S 
  Myocardium 
 
 
NF 
gN(M) 
gN 
ACTB > RPS7 > GAPDH > HMBS > YWHAZ > ABL > GUSB > 18S > HPRT > B2M 
RPS7 > ACTB > GAPDH > YWHAZ > HMBS > ABL > GUSB > 18S > HPRT > B2M 
GAPDH = YWHAZ > RPS7 > ACTB > HMBS > ABL > GUSB > 18S > HPRT > B2M 
  Brain 
 
 
NF 
gN(M) 
gN 
ACTB > ABL > RPS7 = YWHAZ > HMBS > GAPDH > HPRT > GUSB > B2M > 18S 
ACTB > ABL > RPS7 > YWHAZ > HPRT > GAPDH > HMBS > GUSB > B2M > 18S  
ABL = RPS7 > ACTB > GAPDH > HPRT > YWHAZ > HMBS > GUSB > B2M > 18S 
All healthy 
tissues 
combined 
NF 
gN(M) 
gN 
RPS7 > GUSB > YWHAZ > ABL > ACTB > B2M > HMBS > 18S > GAPDH > HPRT 
RPS7 > GUSB > YWHAZ > ABL > ACTB > B2M > HMBS > 18S > GAPDH > HPRT 
GUSB = RPS7 > ABL > YWHAZ > ACTB > B2M > HMBS > 18S > GAPDH > HPRT 
Blood 
 
 
NF 
gN(M) 
gN 
YWHAZ > ABL > GAPDH > B2M > ACTB > GUSB > 18S > HPRT > RPS7 > HMBS 
YWHAZ > B2M > GAPDH > ABL > ACTB > 18S > GUSB > HPRT > RPS7 > HMBS 
YWHAZ = B2M > ACTB > 18S > GAPDH > ABL > GUSB > HPRT > RPS7 > HMBS 
Neoplastic 
tissues 
 
 
NF 
gN(M) 
gN 
RPS7 > ACTB > HMBS > GAPDH > B2M > ABL > 18S > GUSB > YWHAZ > HPRT 
ACTB > RPS7 > HMBS > GAPDH > B2M > 18S > ABL > GUSB > YWHAZ > HPRT 
GAPDH = HMBS > 18S > RPS7 > ACTB > B2M > ABL > GUSB > YWHAZ > HPRT 
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7  Appendix 
Appendix 1: geNorm output files 
Average expression stability values calculated by the geNorm program for 
reference genes included in this study and graph showing the optimal number 
of reference genes for normalization. Output files are shown for a) adrenal 
gland, b) pancreas, c) parathyroid, d) thyroid, e) bone marrow, f) lymph node, 
g) spleen, h) parotid gland, i) duodenum, j) ileum, k) liver, l) kidney, m) 
myocardium, n) brain, o) blood, p) neoplastic tissues, q) all 14 healthy tissues 
combined, r) all endocrine tissues, s) all lymphoid tissues, and t) all 
gastrointestinal tissues. 
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a) geNorm output: Adrenal gland
Average expression stability values of remaining control genes
0.3
0.35
0.4
0.45
0.5
0.55
0.6
0.65
0.7
GUSB HMBS ACTB B2M ABL YWHAZ HPRT RPS7 GAPDH
18S
<:::::  Least stable genes             Most stable genes ::::>
A
ve
ra
ge
 e
xp
re
ss
io
n 
st
ab
ili
ty
 M
Determination of the optimal number of control genes for normalization
0.106
0.095
0.085
0.109
0.085
0.077
0.081
0.074
0.000
0.020
0.040
0.060
0.080
0.100
0.120
V2/3 V3/4 V4/5 V5/6 V6/7 V7/8 V8/9 V9/10
Pairwise Variations  
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Average expression stability values of remaining control genes
0.5
0.7
0.9
1.1
1.3
1.5
1.7
1.9
2.1
2.3
ACTB HPRT GAPDH 18S ABL B2M HMBS YWHAZ GUSB
RPS7
<:::::  Least stable genes             Most stable genes ::::>
A
ve
ra
ge
 e
xp
re
ss
io
n 
st
ab
ili
ty
 M
b) geNorm output: Pancreas
Determination of the optimal number of control genes for normalization
0.274 0.274
0.199
0.254
0.220
0.237
0.255
0.295
0.000
0.050
0.100
0.150
0.200
0.250
0.300
0.350
V2/3 V3/4 V4/5 V5/6 V6/7 V7/8 V8/9 V9/10
Pairwise Variations  
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c) geNorm output: Parathyroid
Average expression stability values of remaining control genes
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
1.1
1.2
HPRT 18S GUSB B2M YWHAZ ABL HMBS ACTB GAPDH
RPS7
<:::::  Least stable genes             Most stable genes ::::>
A
ve
ra
ge
 e
xp
re
ss
io
n 
st
ab
ili
ty
 M
Determination of the optimal number of control genes for normalization
0.179
0.133
0.119 0.124
0.131
0.109
0.144
0.155
0.000
0.020
0.040
0.060
0.080
0.100
0.120
0.140
0.160
0.180
0.200
V2/3 V3/4 V4/5 V5/6 V6/7 V7/8 V8/9 V9/10
Pairwise Variations  
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Average expression stability values of remaining control genes
0.5
0.6
0.7
0.8
0.9
1
1.1
1.2
1.3
1.4
1.5
HPRT GAPDH 18S ABL RPS7 YWHAZ B2M GUSB ACTB
HMBS
<:::::  Least stable genes             Most stable genes ::::>
A
ve
ra
ge
 e
xp
re
ss
io
n 
st
ab
ili
ty
 M
d) geNorm output: Thyroid
Determination of the optimal number of control genes for normalization
0.195
0.161
0.133 0.137
0.148
0.182
0.214
0.183
0.000
0.050
0.100
0.150
0.200
0.250
V2/3 V3/4 V4/5 V5/6 V6/7 V7/8 V8/9 V9/10
Pairwise Variations
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e) geNorm output: Bone marrow
Average expression stability values of remaining control genes
0.8
1
1.2
1.4
1.6
1.8
2
GAPDH HPRT 18S B2M ABL RPS7 GUSB HMBS ACTB 
YWHAZ 
<:::::  Least stable genes             Most stable genes ::::>
Average expression stability M
Determination of the optimal number of control genes for normalization
0.308
0.250
0.206 
0.165
0.183
0.225 0.234 0.222
0.000
0.050
0.100
0.150
0.200
0.250
0.300
0.350
V2/3 V3/4 V4/5 V5/6 V6/7 V7/8 V8/9 V9/1
Pairwise Variations
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f) geNorm output: Mesenteric lymph node
Average expression stability values of remaining control genes
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
1.1
HPRT 18S RPS7 GAPDH HMBS GUSB ACTB YWHAZ ABL
B2M
<:::::  Least stable genes             Most stable genes ::::>
A
ve
ra
ge
 e
xp
re
ss
io
n 
st
ab
ili
ty
 M
Determination of the optimal number of control genes for normalization
0.131
0.155
0.106 0.109
0.093
0.087
0.132
0.151
0.000
0.020
0.040
0.060
0.080
0.100
0.120
0.140
0.160
0.180
V2/3 V3/4 V4/5 V5/6 V6/7 V7/8 V8/9 V9/10
Pairwise Variations  
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g) geNorm output: Spleen
Average expression stability values of remaining control genes
0.4
0.5
0.6
0.7
0.8
0.9
1
1.1
1.2
1.3
1.4
18S GAPDH HPRT YWHAZ HMBS ABL RPS7 GUSB ACTB
B2M
<:::::  Least stable genes             Most stable genes ::::>
A
ve
ra
ge
 e
xp
re
ss
io
n 
st
ab
ili
ty
 M
Determination of the optimal number of control genes for normalization
0.216
0.175
0.159
0.138 0.134
0.159
0.140
0.192
0.000
0.050
0.100
0.150
0.200
0.250
V2/3 V3/4 V4/5 V5/6 V6/7 V7/8 V8/9 V9/10
Pairwise Variations  
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h) geNorm output: Parotid gland
Average expression stability values of remaining control genes
0.4
0.6
0.8
1
1.2
1.4
1.6
18S GUSB GAPDH HPRT B2M YWHAZ RPS7 HMBS ABL
ACTB
<:::::  Least stable genes             Most stable genes ::::>
A
ve
ra
ge
 e
xp
re
ss
io
n 
st
ab
ili
ty
 M
Determination of the optimal number of control genes for normalization
0.205
0.148 0.146
0.129
0.154
0.164 0.167
0.221
0.000
0.050
0.100
0.150
0.200
0.250
V2/3 V3/4 V4/5 V5/6 V6/7 V7/8 V8/9 V9/10
Pairwise Variations  
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i) geNorm output: Duodenum
Average expression stability values of remaining control genes
0.8
1
1.2
1.4
1.6
1.8
2
HPRT B2M GUSB 18S ABL YWHAZ GAPDH RPS7 ACTB
HMBS
<:::::  Least stable genes             Most stable genes ::::>
A
ve
ra
ge
 e
xp
re
ss
io
n 
st
ab
ili
ty
 M
Determination of the optimal number of control genes for normalization
0.334
0.251
0.215 0.215
0.197
0.222
0.239
0.262
0.000
0.050
0.100
0.150
0.200
0.250
0.300
0.350
0.400
V2/3 V3/4 V4/5 V5/6 V6/7 V7/8 V8/9 V9/10
Pairwise Variations
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j) geNorm output: Ileum
Average expression stability values of remaining control genes
0.5
0.6
0.7
0.8
0.9
1
1.1
1.2
1.3
1.4
1.5
18S B2M HPRT RPS7 GAPDH GUSB ABL HMBS ACTB
YWHAZ
<:::::  Least stable genes             Most stable genes ::::>
A
ve
ra
ge
 e
xp
re
ss
io
n 
st
ab
ili
ty
 M
Determination of the optimal number of control genes for normalization
0.199
0.172
0.164
0.153
0.175
0.167 0.170
0.175
0.000
0.050
0.100
0.150
0.200
0.250
V2/3 V3/4 V4/5 V5/6 V6/7 V7/8 V8/9 V9/10
Pairwise Variations  
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k) geNorm output: Liver
Average expression stability values of remaining control genes
0.4
0.5
0.6
0.7
0.8
0.9
1
1.1
18S B2M RPS7 YWHAZ GUSB HPRT GAPDH ABL ACTB
HMBS
<:::::  Least stable genes             Most stable genes ::::>
A
ve
ra
ge
 e
xp
re
ss
io
n 
st
ab
ili
ty
 M
Determination of the optimal number of control genes for normalization
0.182
0.140
0.118
0.107
0.096
0.087
0.120
0.161
0.000
0.020
0.040
0.060
0.080
0.100
0.120
0.140
0.160
0.180
0.200
V2/3 V3/4 V4/5 V5/6 V6/7 V7/8 V8/9 V9/10
Pairwise Variations  
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l) geNorm output: Kidney
Average expression stability values of remaining control genes
0.5
0.6
0.7
0.8
0.9
1
1.1
1.2
18S HPRT B2M GUSB GAPDH HMBS ACTB ABL RPS7
YWHAZ
<:::::  Least stable genes             Most stable genes ::::>
A
ve
ra
ge
 e
xp
re
ss
io
n 
st
ab
ili
ty
 M
Determination of the optimal number of control genes for normalization
0.177
0.148
0.111 0.106 0.110
0.122
0.134
0.202
0.000
0.050
0.100
0.150
0.200
0.250
V2/3 V3/4 V4/5 V5/6 V6/7 V7/8 V8/9 V9/10
Pairwise Variations  
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m) geNorm output: Myocardium
Average expression stability values of remaining control genes
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
<:::::  Least stable genes             Most stable genes ::::>
A
ve
ra
ge
 e
xp
re
ss
io
n 
st
ab
ili
ty
 M
Determination of the optimal number of control genes for normalization
0.127
0.085 0.084
0.076
0.098 0.095
0.122
0.161
0.000
0.020
0.040
0.060
0.080
0.100
0.120
0.140
0.160
0.180
V2/3 V3/4 V4/5 V5/6 V6/7 V7/8 V8/9 V9/10
Pairwise Variations
B2M HPRT 18S GUSB ABL HMBS ACTB RPS7 GAPDH
YWHAZ
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n) geNorm output: Brain
Average expression stability values of remaining control genes
0.3
0.4
0.5
0.6
0.7
0.8
0.9
18S B2M GUSB HMBS YWHAZ HPRT GAPDH ACTB ABL
RPS7
<:::::  Least stable genes             Most stable genes ::::>
A
ve
ra
ge
 e
xp
re
ss
io
n 
st
ab
ili
ty
 M
Determination of the optimal number of control genes for normalization
0.123
0.106
0.088
0.067
0.077
0.065
0.088
0.153
0.000
0.020
0.040
0.060
0.080
0.100
0.120
0.140
0.160
0.180
V2/3 V3/4 V4/5 V5/6 V6/7 V7/8 V8/9 V9/10
Pairwise Variations  
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o) geNorm output: Blood
Average expression stability values of remaining control genes
0.3
0.5
0.7
0.9
1.1
1.3
1.5
HMBS RPS7 HPRT GUSB ABL GAPDH 18S ACTB B2M
YWHAZ
<:::::  Least stable genes             Most stable genes ::::>
A
ve
ra
ge
 e
xp
re
ss
io
n 
st
ab
ili
ty
 M
Determination of the optimal number of control genes for normalization
0.168
0.177
0.165 0.161
0.154
0.139
0.158
0.172
0.000
0.020
0.040
0.060
0.080
0.100
0.120
0.140
0.160
0.180
0.200
V2/3 V3/4 V4/5 V5/6 V6/7 V7/8 V8/9 V9/10
Pairwise Variations  
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p) geNorm output: Neoplastic tissues
Average expression stability values of remaining control genes
0.6
0.7
0.8
0.9
1
1.1
1.2
HPRT YWHAZ GUSB ABL B2M ACTB RPS7 18S GAPDH
HMBS
<:::::  Least stable genes             Most stable genes ::::>
A
ve
ra
ge
 e
xp
re
ss
io
n 
st
ab
ili
ty
 M
Determination of the optimal number of control genes for normalization
0.233
0.162
0.153
0.121
0.148
0.128
0.117 0.116
0.000
0.050
0.100
0.150
0.200
0.250
V2/3 V3/4 V4/5 V5/6 V6/7 V7/8 V8/9 V9/10
Pairwise Variations  
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q) geNorm output: All healthy tissues
Average expression stability values of remaining control genes
1.1
1.2
1.3
1.4
1.5
1.6
1.7
1.8
1.9
2
HPRT GAPDH 18S HMBS B2M ACTB YWHAZ ABL GUSB
RPS7
<:::::  Least stable genes             Most stable genes ::::>
A
ve
ra
ge
 e
xp
re
ss
io
n 
st
ab
ili
ty
 M
Determination of the optimal number of control genes for normalization
0.439
0.321
0.264
0.247 0.246
0.207 0.196
0.180
0.000
0.050
0.100
0.150
0.200
0.250
0.300
0.350
0.400
0.450
0.500
V2/3 V3/4 V4/5 V5/6 V6/7 V7/8 V8/9 V9/10
Pairwise Variations  
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r) geNorm output: Endocrine tissues
Average expression stability values of remaining control genes
0.9
1
1.1
1.2
1.3
1.4
1.5
1.6
1.7
HPRT ACTB GAPDH 18S ABL RPS7 YWHAZ GUSB B2M
HMBS
<:::::  Least stable genes             Most stable genes ::::>
A
ve
ra
ge
 e
xp
re
ss
io
n 
st
ab
ili
ty
 M
Determination of the optimal number of control genes for normalization
0.293
0.219
0.183 0.178
0.193
0.203 0.202
0.189
0.000
0.050
0.100
0.150
0.200
0.250
0.300
0.350
V2/3 V3/4 V4/5 V5/6 V6/7 V7/8 V8/9 V9/10
Pairwise Variations
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s) geNorm output: Lymphoid tissues
Average expression stability values of remaining control genes
0.8
1
1.2
1.4
1.6
1.8
2
2.2
HMBS 18S HPRT GAPDH B2M ABL YWHAZ ACTB GUSB
RPS7
<:::::  Least stable genes             Most stable genes ::::>
A
ve
ra
ge
 e
xp
re
ss
io
n 
st
ab
ili
ty
 M
Determination of the optimal number of control genes for normalization
0.346
0.251
0.228
0.190
0.245 0.247
0.227
0.273
0.000
0.050
0.100
0.150
0.200
0.250
0.300
0.350
0.400
V2/3 V3/4 V4/5 V5/6 V6/7 V7/8 V8/9 V9/10
Pairwise Variations  
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t) geNorm output: Gastrointestinal tissues
Average expression stability values of remaining control genes
0.9
1
1.1
1.2
1.3
1.4
1.5
1.6
1.7
1.8
HPRT 18S GUSB B2M GAPDH YWHAZ ACTB RPS7 ABL
HMBS
<:::::  Least stable genes             Most stable genes ::::>
A
ve
ra
ge
 e
xp
re
ss
io
n 
st
ab
ili
ty
 M
Determination of the optimal number of control genes for normalization
0.308
0.292
0.228
0.185
0.209
0.197
0.187
0.204
0.000
0.050
0.100
0.150
0.200
0.250
0.300
0.350
V2/3 V3/4 V4/5 V5/6 V6/7 V7/8 V8/9 V9/10
Pairwise Variations  
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Appendix 2: NormFinder output 
Stability values and standard errors calculated by the NormFinder program. In 
addition, a gene ranking for every tissue is shown 
 
 
 
 
 
 
Lymphatic
tissues
Endocrine
tissues
Genename Stability value Standard error Ranking Genename Stability value Standard error Ranking
ABL 0.991 0.144 5 ABL 0.802 0.101 6
ACTB 0.636 0.108 3 ACTB 1.227 0.143 9
GAPDH 1.036 0.149 6 GAPDH 1.028 0.123 8
B2M 1.078 0.153 7 B2M 0.464 0.072 3
GUSB 0.301 0.096 2 GUSB 0.462 0.072 2
HMBS 1.867 0.247 10 HMBS 0.518 0.076 5
HPRT 1.204 0.168 8 HPRT 1.284 0.149 10
RPS7 0.278 0.098 1 RPS7 0.509 0.075 4
YWHAZ 0.707 0.115 4 YWHAZ 0.450 0.072 1
18S 1.273 0.176 9 18S 1.023 0.123 7
Gastrointestinal
tissues
All tissues
Genename Stability value Standard error Ranking Genename Stability value Standard error Ranking
ABL 0.626 0.103 5 ABL 0.816 0.055 4
ACTB 0.490 0.091 1 ACTB 0.881 0.058 5
GAPDH 0.700 0.111 6 GAPDH 1.186 0.074 9
B2M 1.099 0.157 8 B2M 1.019 0.065 6
GUSB 1.008 0.146 7 GUSB 0.693 0.050 2
HMBS 0.546 0.095 2 HMBS 1.025 0.066 7
HPRT 1.387 0.192 10 HPRT 1.208 0.075 10
RPS7 0.588 0.099 4 RPS7 0.449 0.041 1
YWHAZ 0.547 0.095 3 YWHAZ 0.804 0.055 3
18S 1.199 0.169 9 18S 1.143 0.072 8  
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Adrenal gland Pancreas
Gene name Stability value Standard error Ranking Gene name Stability value Standard error Ranking
ABL 0.273 0.073 3 ABL 1.190 0.265 7
ACTB 0.305 0.079 5 ACTB 2.025 0.423 10
GAPDH 0.354 0.088 6 GAPDH 1.125 0.253 6
B2M 0.296 0.077 4 B2M 0.566 0.166 5
GUSB 0.504 0.118 10 GUSB 0.306 0.158 2
HMBS 0.435 0.104 8 HMBS 0.541 0.164 4
HPRT 0.147 0.056 1 HPRT 1.520 0.326 9
RPS7 0.243 0.068 2 RPS7 0.200 0.188 1
YWHAZ 0.452 0.107 9 YWHAZ 0.384 0.154 3
18S 0.365 0.090 7 18S 1.321 0.289 8
Parathyroid Thyroid
Gene name Stability value Standard error Ranking Gene name Stability value Standard error Ranking
ABL 0.470 0.159 6 ABL 0.701 0.187 7
ACTB 0.065 0.203 1 ACTB 0.213 0.127 2
GAPDH 0.327 0.130 3 GAPDH 1.230 0.300 9
B2M 0.627 0.198 7 B2M 0.378 0.132 5
GUSB 0.692 0.214 8 GUSB 0.205 0.128 1
HMBS 0.441 0.153 4 HMBS 0.358 0.130 4
HPRT 1.062 0.314 10 HPRT 1.250 0.304 10
RPS7 0.159 0.121 2 RPS7 0.487 0.147 6
YWHAZ 0.469 0.159 5 YWHAZ 0.271 0.124 3
18S 0.749 0.230 9 18S 1.215 0.297 8
Bone marrow Mesenteric lymph node
Gene name Stability value Standard error Ranking Gene name Stability value Standard error Ranking
ABL 0.456 0.152 3 ABL 0.370 0.108 6
ACTB 0.649 0.180 6 ACTB 0.222 0.087 2
GAPDH 1.512 0.349 10 GAPDH 0.484 0.129 8
B2M 0.857 0.217 7 B2M 0.303 0.097 3
GUSB 0.558 0.165 4 GUSB 0.194 0.086 1
HMBS 0.388 0.146 2 HMBS 0.326 0.100 4
HPRT 1.476 0.342 9 HPRT 1.035 0.249 10
RPS7 0.320 0.144 1 RPS7 0.431 0.119 7
YWHAZ 0.620 0.175 5 YWHAZ 0.328 0.101 5
18S 1.322 0.310 8 18S 0.852 0.208 9
Spleen Parotid gland
Gene name Stability value Standard error Ranking Gene name Stability value Standard error Ranking
ABL 0.447 0.134 4 ABL 0.141 0.155 1
ACTB 0.384 0.125 3 ACTB 0.248 0.130 2
GAPDH 0.901 0.225 9 GAPDH 0.871 0.235 8
B2M 0.453 0.135 5 B2M 0.535 0.164 6
GUSB 0.159 0.122 1 GUSB 1.040 0.273 9
HMBS 0.581 0.158 6 HMBS 0.428 0.146 5
HPRT 0.855 0.215 8 HPRT 0.838 0.227 7
RPS7 0.255 0.112 2 RPS7 0.261 0.130 3
YWHAZ 0.629 0.168 7 YWHAZ 0.349 0.135 4
18S 1.316 0.317 10 18S 1.518 0.386 10
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Duodenum Ileum
Gene name Stability value Standard error Ranking Gene name Stability value Standard error Ranking
ABL 0.775 0.218 6 ABL 0.232 0.119 2
ACTB 0.513 0.176 3 ACTB 0.351 0.125 4
GAPDH 0.413 0.167 2 GAPDH 0.597 0.164 5
B2M 1.584 0.387 9 B2M 1.015 0.251 9
GUSB 1.143 0.291 8 GUSB 0.614 0.168 6
HMBS 0.609 0.190 4 HMBS 0.093 0.186 1
HPRT 1.790 0.433 10 HPRT 1.002 0.248 8
RPS7 0.074 0.415 1 RPS7 0.827 0.211 7
YWHAZ 0.727 0.209 5 YWHAZ 0.331 0.123 3
18S 1.022 0.266 7 18S 1.192 0.290 10
Liver Kidney
Gene name Stability value Standard error Ranking Gene name Stability value Standard error Ranking
ABL 0.453 0.131 7 ABL 0.279 0.088 3
ACTB 0.572 0.156 8 ACTB 0.310 0.091 4
GAPDH 0.283 0.101 2 GAPDH 0.537 0.122 7
B2M 0.682 0.181 9 B2M 0.715 0.152 8
GUSB 0.282 0.100 1 GUSB 0.452 0.109 6
HMBS 0.337 0.109 5 HMBS 0.368 0.097 5
HPRT 0.315 0.105 4 HPRT 0.830 0.172 9
RPS7 0.289 0.102 3 RPS7 0.222 0.085 2
YWHAZ 0.402 0.121 6 YWHAZ 0.081 0.129 1
18S 1.110 0.282 10 18S 1.391 0.276 10
Myocardium Brain
Gene name Stability value Standard error Ranking Gene name Stability value Standard error Ranking
ABL 0.393 0.111 6 ABL 0.239 0.069 2
ACTB 0.105 0.094 1 ACTB 0.151 0.062 1
GAPDH 0.193 0.083 3 GAPDH 0.313 0.079 5
B2M 1.108 0.265 10 B2M 0.511 0.113 8
GUSB 0.435 0.118 7 GUSB 0.347 0.084 7
HMBS 0.225 0.085 4 HMBS 0.298 0.077 4
HPRT 0.757 0.186 9 HPRT 0.334 0.082 6
RPS7 0.109 0.092 2 RPS7 0.249 0.070 3
YWHAZ 0.265 0.090 5 YWHAZ 0.249 0.070 3
18S 0.533 0.138 8 18S 1.052 0.217 9
Blood Neoplastic tissues
Gene name Stability value Standard error Ranking Gene name Stability value Standard error Ranking
ABL 0.354 0.127 2 ABL 0.625 0.145 6
ACTB 0.524 0.156 5 ACTB 0.324 0.094 2
GAPDH 0.368 0.129 3 GAPDH 0.467 0.116 4
B2M 0.390 0.132 4 B2M 0.504 0.122 5
GUSB 0.577 0.167 6 GUSB 0.632 0.146 8
HMBS 1.174 0.302 10 HMBS 0.381 0.102 3
HPRT 0.877 0.233 8 HPRT 0.785 0.176 10
RPS7 0.887 0.235 9 RPS7 0.318 0.093 1
YWHAZ 0.350 0.126 1 YWHAZ 0.696 0.158 9
18S 0.662 0.185 7 18S 0.626 0.145 7  
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